Skip to content

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

PRESS RELEASES

Choose Year
Search Press Releases

Found 215 Results

February 5, 2018

Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director

December 21, 2017

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder

December 19, 2017

Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia

December 11, 2017

Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors

December 11, 2017

Minerva Neurosciences Names Richard Russell President

December 6, 2017

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder

November 8, 2017

Minerva Neurosciences to Present at Jefferies 2017 London Healthcare Conference on November 15, 2017

November 6, 2017

Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates

October 31, 2017

Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy

October 30, 2017

Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017

«...11 121314 15...»

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803

Company

About Us
Leadership
Board of Directors
Contact

Science

Our Approach
Pipeline
Publications
Clinical Trials

Investors

Investors Overview
News
Events
SEC Filings
Stock Information
Corporate Governance
FAQs

© 2026 Minerva Neurosciences, Inc.

Privacy Policy
Terms of Use
Accessibility Statement
Cookie Policy

Scroll to Top